RxDoctor Payments DataLook up a doctor →

Natalie Wallace, MD

Hematology & Oncology · Anchorage, AKNPI 1386059061

Payments from drug & device makers

$7,983in general payments, 2019–2025

Across 333 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$863
  • Johnson & Johnson$678
  • Novartis$565
  • AbbVie$442
  • E.r. Squibb & Sons, L.L.C.$425
  • Bristol Myers Squibb$352
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,39293%
  • Education$5917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)34$863
Johnson & Johnson(2 entities)28$678
Novartis32$565
AbbVie16$442
E.r. Squibb & Sons, L.L.C.20$425
Bristol Myers Squibb14$352
GSK12$271
Amgen5$248
Seagen Inc.13$228
Pfizer13$211
Sobi, Inc5$208
Ipsen Biopharmaceuticals, Inc5$193
Gilead(2 entities)9$193
AVEO Pharmaceuticals, Inc.4$174
Boehringer Ingelheim7$160
Daiichi Sankyo Inc.4$159
EMD Serono, Inc.7$156
Regeneron Healthcare Solutions, Inc.4$126
Sanofi4$122
Merck5$121
Coherus Oncology, Inc.5$110
Rigel Pharmaceuticals, Inc.4$105
Genentech USA, Inc.4$100
Blueprint Medicines Corporation4$97
Array Biopharma Inc5$90
Puma Biotechnology, Inc.4$88
Incyte Corporation4$86
Pharmacyclics LLC, An Abbvie Company3$79
Astellas Pharma US Inc3$77
Tempus AI, Inc3$69
Stemline Therapeutics Inc.2$68
Adaptive Biotechnologies Corporation3$67
Servier Pharmaceuticals LLC3$63
Genmab U.S., Inc.2$61
Beigene USA, Inc.2$52
Mirati Therapeutics, Inc.2$51
ADC Therapeutics America, Inc.2$46
Pharmacosmos Therapeutics Inc.2$44
Lilly USA, LLC2$43
Taiho Oncology, Inc.2$40
Beone Medicines USA, Inc.2$36
Deciphera Pharmaceuticals Inc.2$35
Kyowa Kirin, Inc.2$35
Apellis Pharmaceuticals, Inc.1$34
Exelixis Inc.1$34
Immunocore Limited1$33
Acrotech Biopharma Inc.2$31
Eisai Inc.2$30
Tersera Therapeutics LLC1$30
Takeda Pharmaceuticals U.S.A., Inc.1$30
Recordati_rare_diseases_inc.1$26
G1 Therapeutics, Inc.1$24
Fennec Pharmaceuticals, Inc.1$24
Jazz Pharmaceuticals Inc.1$24
Roche Diagnostics Corporation1$23
Alnylam Pharmaceuticals Inc.1$23
Chiesi USA, Inc.1$22
Agios Pharmaceuticals, Inc.1$21
Dova Pharmaceuticals1$18
Epizyme, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,527,257
Medicare patients
400
Services billed
116,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TabrectaCapmatinib Hydrochloride12$283,675
TagrissoOsimertinib Mesylate12$213,090
KisqaliRibociclib Succinate18$187,702
LynparzaOlaparib11$178,483
VerzenioAbemaciclib16$178,056
EliquisApixaban44$52,142
XareltoRivaroxaban15$12,673
Anastrozole81$2,346
Letrozole48$1,426
Mirtazapine28$825
Ondansetron OdtOndansetron34$671
Tamoxifen Citrate12$552
Hydroxyurea28$374
Acyclovir11$359
Lidocaine-PrilocaineLidocaine/Prilocaine18$229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTabrecta, Kisqali$565$471,37730 claims
AstraZenecaTagrisso, Lynparza$863$391,57323 claims
Lilly USA, LLCVerzenio$43$178,05616 claims
PfizerEliquis$211$52,14244 claims
Johnson & JohnsonXarelto$678$12,67315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →